Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease
Peters J, Longbrake E. Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease. Multiple Sclerosis And Related Disorders 2022, 68: 104400. PMID: 36544307, PMCID: PMC10075342, DOI: 10.1016/j.msard.2022.104400.Peer-Reviewed Original ResearchConceptsLong-term B-cell depletionB-cell depletionReal-world cohortSevere infectionsTotal infectionsSingle-center observational studyEffective disease-modifying therapiesInfectious adverse effectsFormer smoking statusRisk of hospitalizationAutoimmune neurologic diseasesAutoimmune neurologic disordersDisease-modifying therapiesYears of treatmentRate of infectionLong-term useImmunologic changesLaboratory abnormalitiesClinical factorsSmoking statusHigher BMIMultiple sclerosisSerious infectionsNeurologic disordersFemale genderRisks of Minor and Severe Infections in Multiple Sclerosis Patients Treated with Long-term B-cell Depletion (P13-4.011)
Peters J, Longbrake E. Risks of Minor and Severe Infections in Multiple Sclerosis Patients Treated with Long-term B-cell Depletion (P13-4.011). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1270.Peer-Reviewed Original ResearchLong-term B-cell depletionB-cell depletionMultiple sclerosis patientsSclerosis patientsSevere infectionsPatientsInfection